Related Experiment Videos
Development of Recombinant Measles Virus-Based Vaccines
Michael D Mühlebach1, Stefan Hutzler2
1Product Testing of IVMP, Division Veterinary Medicine, Paul-Ehrlich-Institut, Paul-Ehrlich-Str. 51-59, 63225, Langen, Germany. Michael.Muehlebach@pei.de.
Methods in Molecular Biology (Clifton, N.J.)
|April 5, 2017
Summary
Recombinant measles virus (MV) vaccines are developed using plasmid DNA and a reverse genetics system. These vaccines present foreign pathogen antigens, inducing strong immune responses and demonstrating protective capacity in preclinical studies.
Area of Science:
- Virology
- Vaccinology
- Molecular Biology
Background:
- Live-attenuated measles vaccines (MV) are highly effective and safe.
- Reverse genetics systems enable manipulation of MV genomes for recombinant virus generation.
Purpose of the Study:
- To describe the development of recombinant MV-based vaccines from plasmid DNA.
- To highlight the potential of recombinant MVs for presenting foreign antigens and inducing immune responses.
Main Methods:
- Cloning foreign antigen-encoding genes into MV vaccine strain genomes.
- Generating recombinant MV via transfection of rescue cells with viral RNA and proteins.
- Isolating, amplifying, and characterizing recombinant viruses in vitro.
Main Results:
- Recombinant MVs successfully present foreign pathogen antigens during replication.
- Robust humoral and cellular immune responses are induced by these recombinant MVs.
- Demonstrated protective capacity in preclinical animal models.
Conclusions:
- Recombinant MV technology offers a promising platform for vaccine development.
- This approach can elicit protective immunity against various pathogens.
- Further evaluation in preclinical models supports their potential efficacy.